Cite
HARVARD Citation
Frontzek, F. et al. (2021). Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet. 8 (4), pp. e267-e277. [Online].